Injective (INJ) is currently trading at $3.53, reflecting a 24-hour decline of approximately 4.15%. The price has experienced a narrow daily range of 0.37%, indicating relatively low volatility in the short term, with a high of $3.90 and a low matching the current price.

Volume stands at around 80,983,411, which translates to a volume-to-market cap ratio of 22.91%. This suggests robust trading activity relative to its market capitalization, although the downward price movement indicates selling pressure prevailing in the market.

The hourly moving averages reveal a bearish trend, with the 8 SMA at $3.70 and the 13 SMA at $3.74, both showing declines of approximately 4.67% and 5.62%, respectively. The 144 SMA, however, is showing a positive trend at $3.46, indicating potential support in the longer-term view.

The 1-hour Relative Strength Index (RSI) is notably low at 25, suggesting that INJ is currently in oversold territory and may experience a short-term reversal. In contrast, the 7-day RSI sits at 54, indicating a more balanced market condition, while the 14-day and 30-day price changes of approximately 19.94% and 21.74%, respectively, reflect a stronger performance over the medium term.

Injective's all-time high of $52.62 set on March 14, 2024, highlights the asset's significant long-term potential, although current market conditions are starkly different. Given the recent downward movement, alongside oversold signals from the 1-hour RSI, there may be an opportunity for a short-term rebound.

Overall, while the bearish momentum is evident in the immediate term, the oversold conditions and historical performance suggest a potential recovery phase might be on the horizon. Therefore, the rating for Injective (INJ) is a Hold, with the recommendation to monitor for signs of reversal before considering new positions or adding to existing ones.